-
公开(公告)号：US20240299560A1
公开(公告)日：2024-09-12
申请号：US18009418
申请日：2021-06-11
申请人： CAREGEN CO, LTD.
发明人： Yong Ji CHUNG , Eun Mi KIM , Seon Soo KIM
CPC分类号： A61K47/554 , A61K47/55 , A61K47/64 , C07K7/06
摘要： The present invention relates to: a deoxycholic acid-peptide conjugate having anti-obesity activity by inhibiting lipid production and promoting lipolysis; and a use for preventing, ameliorating or treating obesity comprising the conjugate as an active ingredient.
-
公开(公告)号：US12037585B2
公开(公告)日：2024-07-16
申请号：US17132803
申请日：2020-12-23
IPC分类号： C12N15/113 , A61K47/54
CPC分类号： C12N15/113 , A61K47/542 , A61K47/549 , A61K47/554 , C12N2310/14 , C12N2310/315 , C12N2310/322 , C12N2310/3515 , C12N2320/32
摘要： This disclosure relates to a therapeutic combination of drugs for the treatment or management of a neurodegenerative disease, the combination comprising: a first conjugate comprising an RNA silencing agent and a first targeting agent that targets the first conjugate to the central nervous system, and a second conjugate comprising an antagonist of the RNA silencing agent and a second targeting agent that targets the second conjugate to a off-target tissue.
-
3.发明公开公开(公告)号：US20240189430A1
公开(公告)日：2024-06-13
申请号：US18546131
申请日：2022-02-17
申请人： LONZA SALES AG
发明人： Aaron NOYES , Eric ZHANG , Wendy BROOM , Chris WARREN , Yaozhong ZHANG , Erika ROSE
CPC分类号： A61K47/549 , A61K47/542 , A61K47/551 , A61K47/554 , A61K47/65 , A61K47/6911
摘要： The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via an optimized linker and an anchoring moiety, which may be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.
-
公开(公告)号：US20240117355A1
公开(公告)日：2024-04-11
申请号：US18018986
申请日：2022-05-23
申请人： TIONLAB THERAPEUTICS
发明人： Duck Soo LIM , Jin-Ho KIM
IPC分类号： C12N15/113 , A61K9/51 , A61K31/337 , A61K31/7105 , A61K47/54 , A61K47/64 , A61K47/69 , A61P35/00
CPC分类号： C12N15/1137 , A61K9/5123 , A61K31/337 , A61K31/7105 , A61K47/548 , A61K47/554 , A61K47/643 , A61K47/6929 , A61P35/00 , C12N2310/14
摘要： According to the present invention, it is possible to provide a drug carrier having excellent bioavailability and improved drug encapsulation efficiency by preparing lipoprotein-mimicking solid lipid nanoparticles having a core-shell structure consisting of albumin-conjugated cholesterol, a fusogenic lipid, a cationic lipid, a triglyceride and a cholesteryl ester.
-
5.发明公开公开(公告)号：US20240024492A1
公开(公告)日：2024-01-25
申请号：US18265603
申请日：2021-12-06
发明人： Hye Won CHUNG , June Hyun PARK , Seung Ya YANG
IPC分类号： A61K47/54 , C12N15/113 , A61P27/02
CPC分类号： A61K47/554 , C12N15/113 , A61K47/542 , A61P27/02
摘要： The present application relates to an asymmetric RNAi-inducing nucleic acid molecule which inhibits the expression of retinoid-related orphan nuclear receptor-beta (ROR-beta) and use thereof, and more particularly to an asymmetric RNAi-inducing nucleic acid molecule comprising an antisense strand comprising a sequence complementary to mRNA encoding ROR-beta, and a sense strand forming complementary bonds with the antisense strand, and a pharmaceutical composition for ameliorating or treating a retinal disease, comprising the asymmetric RNAi-inducing nucleic acid molecule.
-
公开(公告)号：US11833209B2
公开(公告)日：2023-12-05
申请号：US17300655
申请日：2021-09-10
发明人： David Stover , Dhruba Bharali , Bruce A Hay , Tahmineh Safaie
CPC分类号： A61K47/554 , A61K47/548 , A61K47/549 , A61K47/6911 , A61K47/6929 , A61P35/00
摘要： Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：US20230265123A1
公开(公告)日：2023-08-24
申请号：US18041289
申请日：2021-08-10
发明人： Reynold Homan
CPC分类号： C07K7/08 , A61K9/5123 , A61P35/00 , A61K47/554 , A61K47/542 , A61K51/08 , A61K51/0408
摘要： Novel amphiphilic peptide, peptide amphiphile lipid micelles, processes for making peptide amphiphile lipid micelles comprising an amphiphilic peptide and phospholipid and optionally comprising a cargo molecule, and methods of use.
-
公开(公告)号：US20230181744A1
公开(公告)日：2023-06-15
申请号：US17996867
申请日：2021-04-23
申请人： FUDAN UNIVERSITY
CPC分类号： A61K47/545 , A61K47/55 , A61K41/00 , A61K47/554 , A61P3/06
摘要： The present invention relates to the field of biomedicine, and specifically relates to an “LC3 binding portion-lipid droplet binding portion-conjugate” formed by means of covalently linking a structure capable of binding LC3 and a structure capable of binding lipid droplets, and a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, and the use thereof in the preparation of drugs for preventing or treating lipid metabolism-related diseases.
-
公开(公告)号：US11648316B2
公开(公告)日：2023-05-16
申请号：US16763844
申请日：2018-10-10
申请人： ICURE BNP CO., LTD.
发明人： Jin Woo Park , Young Ro Byun , Young Kweon Choi , Kwan Young Chang , Jae Bum Lee
IPC分类号： A61K47/54 , A61K9/00 , A61K31/519 , A61K47/10 , A61K9/113 , A61K9/20 , A61K9/48 , A61K31/353 , A61K31/513 , A61K31/575 , A61K47/26 , A61K47/40 , A61K47/44
CPC分类号： A61K47/554 , A61K9/0053 , A61K9/113 , A61K9/2095 , A61K9/4833 , A61K31/353 , A61K31/513 , A61K31/519 , A61K31/575 , A61K47/10 , A61K47/26 , A61K47/40 , A61K47/44
摘要： The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.
-
公开(公告)号：US20190247414A1
公开(公告)日：2019-08-15
申请号：US16335017
申请日：2017-09-25
发明人： Takanori Yokota , Tetsuya Nagata
IPC分类号： A61K31/711 , A61K47/22 , A61K47/28 , C12N15/113 , A61K47/54 , A61P27/02 , A61P25/00 , A61K31/7125 , A61K9/00
CPC分类号： A61K31/711 , A61K9/0019 , A61K31/7088 , A61K31/7125 , A61K47/22 , A61K47/28 , A61K47/542 , A61K47/554 , A61K48/00 , A61P25/00 , A61P27/02 , C12N15/09 , C12N15/113
摘要： The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the expression level of a target transcription product in the central nervous system and/or retina of a subject, the composition including a nucleic acid complex that includes a first nucleic acid strand and a second nucleic acid strand, wherein: the first nucleic acid strand comprises a base sequence capable of hybridizing with at least part of the target transcription product and has an antisense effect on the target transcription product; the second nucleic acid strand comprises a base sequence complementary to the first nucleic acid strand and is conjugated to tocopherol, cholesterol, or an analog thereof; and the first nucleic acid strand is annealed to the second nucleic acid strand.
-
-
-
-
-
-
-
-
-
搜索结果
611 条记录 (耗时 0.033 秒)
